# Manuel Praga

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/manuel-praga/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,743 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 78 |
| i10-index | 272 |
| Last Known Institution | Universidad Complutense de Madrid |
| OpenAlex ID | https://openalex.org/A5052017202 |
| ORCID iD | https://orcid.org/0000-0001-9270-1071 |
| Works | 590 |

## Researcher papers

Showing 12 of 15.

- [Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis](https://scholariq.org/papers/joint-european-league-against-rheumatism-and-european-renal-association-european/)
- [2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis](https://scholariq.org/papers/2019-update-of-the-joint-european-league-against-rheumatism-and-european-renal/)
- [Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments](https://scholariq.org/papers/validation-of-the-oxford-classification-of-iga-nephropathy-in-cohorts-with/)
- [Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease](https://scholariq.org/papers/fatty-kidney-emerging-role-of-ectopic-lipid-in-obesity-related-renal-disease/)
- [Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial](https://scholariq.org/papers/targeted-release-budesonide-versus-placebo-in-patients-with-iga-nephropathy/)
- [Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials](https://scholariq.org/papers/change-in-albuminuria-as-a-surrogate-endpoint-for-progression-of-kidney-disease/)
- [Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy](https://scholariq.org/papers/influence-of-obesity-on-the-appearance-of-proteinuria-and-renal-insufficiency/)
- [The MEST score provides earlier risk prediction in lgA nephropathy](https://scholariq.org/papers/the-mest-score-provides-earlier-risk-prediction-in-lga-nephropathy/)
- [Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga/)
- [Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso](https://scholariq.org/papers/actualizacion-en-sindrome-hemolitico-uremico-atipico-diagnostico-y-tratamiento/)
- [The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy](https://scholariq.org/papers/the-starmen-trial-indicates-that-alternating-treatment-with-corticosteroids-and/)
- [Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes](https://scholariq.org/papers/non-proteinuric-pathways-in-loss-of-renal-function-in-patients-with-type-2/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions-2/)

## Researcher university

- [Universidad Complutense de Madrid](https://scholariq.org/institutions/universidad-complutense-de-madrid/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.